In this issue:
Discontinuing TDF after extended treatment
Long-term tenofovir or entecavir in HDV/HBV
Tenofovir resistance in chronic HBV
DAAs effectively treat HCV in PWID
DAA-induced SVR: benefits in HCV advanced liver disease
Glecaprevir/pibrentasvir effective in HCV genotype 5 or 6
Block perforin-1 function in fulminant viral hepatitis?
Screening adults for HCV in a low-prevalence area
Use kidneys from HCV-infected donors?
DAAs: mortality benefit in HCV without advanced liver disease
Please login below to download this issue (PDF)